Thirty-one candidates prove the AI platform makes real drugs

“the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery”

“roughly sixty million upfront with the remaining six hundred million tied to milestones and royalties”

“In many ways, Lilly is better than us in some areas of AI”

“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”

“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”

“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”